

Under the Paperwork Reduction Act of 1995, no persons are required to respond to a collection of information unless it contains a valid OMB control number.

Substitute for form 1449B/PTO INFORMATION DISCLOSURE STATEMENT BY APPLICANT Date Submitted: (<i>use as many sheets as necessary</i>)		Complete if Known	
		Application Number	10/677,227
		Filing Date	10/03/2003
		First Named Inventor	Hiroaki ITO
		Group Art Unit	1646
		Examiner Name	Prema MERTZ
1	of 1	Attorney Docket Number	

U.S. PATENT DOCUMENTS

FOREIGN PATENT DOCUMENTS

NON-PATENT LITERATURE DOCUMENTS

Examiner Initials*	Cite No. ¹	Include name of the author (in CAPITAL LETTERS), title of the article (when appropriate), title of the item (book, magazine, journal, serial, symposium, catalog, etc.) date, page(s), volume-issue number(s), publisher, city and/or country where published.	T ⁶
PM	B5	IGAKU, Vol. 51, No. 10, 1996, pgs. 111-121, with Partial Translation.	
PM	B6	Jpn. J. Clin. Immun., Vol. 20, No. 2, 1997, pgs. 87-94.	

Examiner Signature	Prima Merk	Date Considered	12/4/06
--------------------	------------	-----------------	---------

***EXAMINER:** Initial if reference considered, whether or not citation is in conformance with MPEP 609. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.

¹Unique citation designation number. ²See attached Kinds of U.S. Patent Documents. ³Enter Office that issued the document, by the two-letter code (WIPO

⁵Kind of document by the appropriate symbols as indicated on the document under WIPO Standard ST. 16 if possible. ⁶Applicant is to place a check mark here if English language Translation is attached.

English language Translation is attached.

Burden Hour Statement: This form is estimated to take 2.0 hours to complete. Time will vary depending upon the needs of the individual case. Any comments on the amount of time you are required to complete this form should be sent to the Chief Information Officer, U.S. Patent and Trademark Office, P.O. Box 1450, Alexandria, VA 22313-1450. DO NOT SEND FEES OR COMPLETED FORMS TO THIS ADDRESS. SEND TO: Commissioner for Patents, P.O. Box 1450, Alexandria, VA 22313-1450.

Under the Paperwork Reduction Act of 1995, no persons are required to respond to a collection of information unless it contains a valid OMB control number.

Substitute for form 1449B/PTO		Complete if Known		
INFORMATION DISCLOSURE STATEMENT BY APPLICANT Date Submitted: October 3, 2003 <i>(use as many sheets as necessary)</i>		Application Number Filing Date First Named Inventor Group Art Unit Examiner Name Attorney Docket Number	Unassigned 10/677227 10/03/2003 Hiroaki ITO et al. 1646 Unassigned Prema Meng 053466-0365	
Sheet	1	of	2	

U.S. PATENT DOCUMENTS

FOREIGN PATENT DOCUMENTS

FOREIGN PATENT DOCUMENT							
Examiner Initials*	Cite No. ¹	Foreign Patent Document			Name of Patentee or Applicant of Cited Documents	Date of Publication of Cited Document MM-DD-YYYY	Pages, Columns, Lines, Where Relevant Passages or Relevant Figures Appear
		Office ³	Number ⁴	Kind Code ⁵ (if known)			
PM	A1	WO	96/40966	A1	Private Biologicals Corporation	12/19/1996	
	A2	JP	7-324097			12/12/1995	
	A3	JP	8-311098			11/26/1996	
	A4	JP	8-245414			09/24/1996	
	A5	JP	9-235276			09/09/1997	
	A6	JP	8-99996			04/16/1996	
	A7	JP	8-50829			09/03/1996	
	A8	WO	96/40966			12/19/1996	
	A9	WO	96/38481		The Board of Regents of the University of Oklahoma	12/05/1996	
	A10	EP	0 811 384		SEIYAKU et al.	12/10/1997	
	A11	WO	99/64069		Ophidian Pharmaceuticals, Inc.	12/16/1999	

OTHER PRIOR ART - NON PATENT LITERATURE DOCUMENTS

OTHER PRIOR ART - NON PATENT LITERATURE		
Examiner Initials*	Cite No.*	Include name of the author (in CAPITAL LETTERS), title of the article (when appropriate), title of the item (book, magazine, journal, serial, symposium, catalog, etc.) date, page(s), volume-issue number(s), publisher, city and/or country where published.
PM	A12	POWRIE et al., "Inhibition of Th1 Responses Prevents Inflammatory Bowel Disease In scid Mice Reconstituted With CD45Rbhi CD4+ T Cells", <i>Immunity</i> , Vol. 1:553-562, (1994).
	A13	TAKAGI et al., "Blockage Of Interleukin-6 Receptor Ameliorates Joint Disease In Murine Collagen-Induced Arthritis", <i>Arthritis Reumatism</i> , Vol. 41(12):2117-2121, (1998).
	A14	MITSUYAMA et al., "Soluble Interleukin-6 Receptors In Inflammatory Bowel Disease; Relation To Circulating Interleukin-6", <i>Gut</i> , Vol. 36:45-49, (1995).
	A15	VAN DULLEMEN et al., "Treatment Of Crohn's Disease With Anti-Tumor Necrosis Factor Chimeric Monoclonal Antibody (cA2)", <i>Gastroenterology</i> , Vol. 109:129-135, (1995).
	A16	SASAJIMA et al., "Changes in Serum Cytokine Profile During Treatment of Ulcerative Colitis", <i>Journal of Gastroenterology and Hepatology</i> , December 1997, page A274, vol. 12, no. SUPPL., XP-001105732.

Examiner Signature	Prerna Mehta	Date Considered	12/4/06
--------------------	--------------	-----------------	---------

***EXAMINER:** Initial if reference considered, whether or not citation is in conformance with MPEP 809. Draw line through citation if not in conformance and not used. Include copy of this form with next communication to applicant.

¹ Unique citation designation number. ² See attached Kinds of U.S. Patent Documents. ³ Enter Office that issued the document, by the two-letter code (WIPO).

¹Unique citation designation number. ²See attached Kinds of U.S. Patent Document. ³Applicant is to place a check mark here if Standard ST.3). ⁴For Japanese patent documents, the indication of the year of the reign of the Emperor must precede the serial number of the patent document. ⁵Kind of document by the appropriate symbols as indicated on the document under WIPO Standard ST. 18 if possible. ⁶Applicant is to place a check mark here if Translation is attached.

English language Translation is attached.

Burden Hour Statement: This form is estimated to take 2.0 hours to complete. Time will vary depending upon the needs of the individual case. Any comments on the amount of time you are required to complete this form should be sent to the Chief Information Officer, U.S. Patent and Trademark Office, Washington, D.C. 20231. DO NOT SEND FEES OR COMPLETED FORMS TO THIS ADDRESS. SEND TO: Assistant Commissioner for Patents, Washington, D.C. 20231.

Under the Paperwork Reduction Act of 1995, no persons are required to respond to a collection of information unless it contains a
number.

Substitute for form 1449B/PTO		Complete if Known	
INFORMATION DISCLOSURE STATEMENT BY APPLICANT Date Submitted: October 3, 2003 (use as many sheets as necessary)		Application Number Filing Date First Named Inventor Group Art Unit Examiner Name Attorney Docket Number	Unassigned 10/6-772-27 10/03/2003 Hiroaki ITO et al. 1646 Unassigned Prema Meng 053466-0365
Sheet	2	of	2

U.S. PATENT DOCUMENTS

FOREIGN PATENT DOCUMENTS

SEARCHED PRIOR ART - NON PATENT LITERATURE DOCUMENTS

OTHER PRIOR ART - NON PATENT LITERATURE		
Examiner Initials*	Cite No. ¹	Include name of the author (in CAPITAL LETTERS), title of the article (when appropriate), title of the item (book, magazine, journal, serial, symposium, catalog, etc.) date, page(s), volume-issue number(s), publisher, city and/or country where published.
PM	A17	FUNAKOSHI et al., "Spectrum of Cytokine Gene Expression in Intestinal Mucosal Lesions of Crohn's Disease and Ulcerative Colitis", Digestion, January 1998, pages 73-78, vol. 59, no. 1, Basel, China, XP-001064174.
	A18	TATEISHI et al., "Role of Cytokines in Experimental Colitis: Relation to Intestinal Permeability", Digestion, 1997, pages 271-281, vol. 58, no. 3, Basel, China, XP-001095980.
	A19	SEIDMAN et al., "Nutritional Issues in Pediatric inflammatory Bowel Disease", Journal of Pediatric Gastroenterology and Nutrition, 1991, pages 424-438, vol. 12, no. 4, Raven Press, Ltd., New York, XP-001105792.
	A20	ROGLER et al., "Cytokines in Inflammatory Bowel Disease," World J. Surg. Vol. 22, No. 4, April 1998, pp. 382-389.
	A21	KMIEC, "Cytokines in Inflammatory Bowel Disease," Arch. Immunol. Ther. Exp. (Warsz), Vol. 46, No. 3, 1998, pp. 143-155.
	A22	HOGEZAND et al., "Selective Immunomodulation in Patients With Inflammatory Bowel Disease-Future Therapy or Reality?" Neth. J. Med. February 1996, Vol. 48, No. 2, pp. 64-67.

Examiner Signature	Brenna Meng	Date Considered	12/4/06
-----------------------	-------------	--------------------	---------

*EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609. Draw line through citation if not in conformance and not included in this form with next communication to applicant.

¹ Unique citation designation number. ²See attached Kinds of U.S. Patent Documents. ³Enter Office that issued the document, by the two-letter code (WIPO).

⁷Unique citation designation number. See clause 1.1.1 of WIPO Standard ST.3. ⁸For Japanese patent documents, the indication of the year of the reign of the Emperor must precede the serial number. ⁹Applicant is to place a check mark here if the document is a translation. ¹⁰Applicant is to place a check mark here if English language Translation is attached.

English language Translation is attached.

Burden Hour Statement: This form is estimated to take 2.0 hours to complete. Time will vary depending upon the needs of the individual case. Any comments on the amount of time you are required to complete this form should be sent to the Chief Information Officer, U.S. Patent and Trademark Office, Washington, D.C. 20231. DO NOT SEND FEES OR COMPLETED FORMS TO THIS ADDRESS. SEND TO: Assistant Commissioner for Patents, Washington, D.C. 20231.